The Female Health Company (FHC) (NASDAQ:FHCO) reminds and urges its shareholders to vote for the proposed merger with Aspen Park Pharmaceuticals, Inc. (APP) before the upcoming special meeting of FHC shareholders, which will be held on Tuesday, September 20, 2016. FHC's shareholders of record as of July 28, 2016 are permitted to vote.
FHC Shareholders - How to Vote
To ensure that your shares of FHC Common Stock are voted at the special meeting, submit your proxy OR, if your shares of FHC Common Stock are held in the name of a broker, bank or other nominee, contact your broker, bank or other nominee. If you do not vote or do not instruct your broker, bank or other nominee how to vote, it will have the same effect as voting "AGAINST" the approval of the proposed merger.
For shareholders who need assistance voting their shares, or have questions regarding the special meeting, please contact FHC's proxy solicitation firm, D.F. King, Inc., at toll-free (866) 751-6309, or at 48 Wall Street, 22 Floor, New York, New York 10005.
To vote, you will need the control number which appears on your proxy card. If you have not received the proxy materials and voting instructions, either electronically or in the mail, contact your broker, if you have one, or Michele Greco at The Female Health Company, 312-213-9859, mgreco@femalehealthcompany.com.
Below are two convenient ways to vote. FHC highly recommends shareholders vote electronically or by phone. Please have your control number ready while voting. The control number is located on your proxy card.
-- Through the Internet, by visiting a website established for that purpose at www.proxyvote.com and following the instructions; or
-- By calling the toll-free number 1-(800) 690-6903 in the United States, Puerto Rico or Canada on a touch-tone phone and following the recorded instructions.
The FHC Board Recommends Shareholders Vote "FOR" all of the proposals.
FHC's Board of Directors believes the merger is a remarkable opportunity to transform FHC into a more profitable and rapidly growing entity and urges shareholders to vote as soon as possible FOR the proposals.
The FHC Board's rationale is straightforward. FHC is a single product company that has enjoyed a long run as the only provider of an FDA approved female condom. Over the last 20 years, FHC has grown, bringing the FC2 Female Condom to many countries around the world. However, a single product company cannot thrive indefinitely. FHC now faces a more competitive business environment - its intellectual property has not been able to prevent the introduction of several World Health Organization (WHO) approved competitive products - and ever tightening government budgets around the world. Unfortunately, some of the countries with the greatest need for FC2 are also in desperate financial straits.
In order to grow and increase shareholder value, FHC must diversify its opportunities by adding products to its offering. This transaction does exactly that. APP brings multiple near-term products with extremely large market opportunities. The success of any one of APP's products could dwarf sales of FC2. APP has strategically built a portfolio that includes four potentially lower-risk / higher-return products that utilize a regulatory approval pathway, which significantly reduces the time, cost and risk in obtaining FDA approval. As recently announced, APP's Tamsulosin DRS, a proprietary medication for the treatment of benign prostatic hyperplasia (BPH) - a $3.5 billion market, has been cleared by the FDA for the accelerated, 505(b)(2) regulatory approval pathway. The plan is to submit the New Drug Application (NDA) for Tamsulosin DRS in 2017 and, if approved, launch the product in early 2018.
The full meeting agenda is detailed in FHC's definitive proxy statement, which has been filed with the Securities and Exchange Commission and mailed to all FHC stockholders of record as of July 28, 2016, the record date for the special meeting of FHC's shareholders to approve matters relating to the proposed merger. |
